MRSA infections: from classical treatment to suicide drugs

Autores
Drebes, Julia; Künz, Madeleine; Pereira, Claudio Alejandro; Betzel, Christian; Wrenger, Carsten
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.
Fil: Drebes, Julia. Universitat Hamburg; Alemania
Fil: Künz, Madeleine. Universitat Hamburg; Alemania
Fil: Pereira, Claudio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Betzel, Christian. Universitat Hamburg; Alemania
Fil: Wrenger, Carsten. Universidade de Sao Paulo; Brasil
Materia
B Vitamins
Co-Factor Starvation
Drug Discovery
Mrsa
Multi Drug Resistance
Pro-Drug
Suicide Drug
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/20403
Acceder
id CONICETDig_65655e09d748b82feca3573118f73233
oai_identifier_str oai:ri.conicet.gov.ar:11336/20403
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling MRSA infections: from classical treatment to suicide drugsDrebes, JuliaKünz, MadeleinePereira, Claudio AlejandroBetzel, ChristianWrenger, CarstenB VitaminsCo-Factor StarvationDrug DiscoveryMrsaMulti Drug ResistancePro-DrugSuicide Drughttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.Fil: Drebes, Julia. Universitat Hamburg; AlemaniaFil: Künz, Madeleine. Universitat Hamburg; AlemaniaFil: Pereira, Claudio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Betzel, Christian. Universitat Hamburg; AlemaniaFil: Wrenger, Carsten. Universidade de Sao Paulo; BrasilBentham Science Publishers2014-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/20403Drebes, Julia; Künz, Madeleine; Pereira, Claudio Alejandro; Betzel, Christian; Wrenger, Carsten; MRSA infections: from classical treatment to suicide drugs; Bentham Science Publishers; Current Medicinal Chemistry; 21; 15; 2-2014; 1809-18190929-86731875-533XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/118131/articleinfo:eu-repo/semantics/altIdentifier/doi/10.2174/0929867320666131119122520info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:07:46Zoai:ri.conicet.gov.ar:11336/20403instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:07:46.469CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv MRSA infections: from classical treatment to suicide drugs
title MRSA infections: from classical treatment to suicide drugs
spellingShingle MRSA infections: from classical treatment to suicide drugs
Drebes, Julia
B Vitamins
Co-Factor Starvation
Drug Discovery
Mrsa
Multi Drug Resistance
Pro-Drug
Suicide Drug
title_short MRSA infections: from classical treatment to suicide drugs
title_full MRSA infections: from classical treatment to suicide drugs
title_fullStr MRSA infections: from classical treatment to suicide drugs
title_full_unstemmed MRSA infections: from classical treatment to suicide drugs
title_sort MRSA infections: from classical treatment to suicide drugs
dc.creator.none.fl_str_mv Drebes, Julia
Künz, Madeleine
Pereira, Claudio Alejandro
Betzel, Christian
Wrenger, Carsten
author Drebes, Julia
author_facet Drebes, Julia
Künz, Madeleine
Pereira, Claudio Alejandro
Betzel, Christian
Wrenger, Carsten
author_role author
author2 Künz, Madeleine
Pereira, Claudio Alejandro
Betzel, Christian
Wrenger, Carsten
author2_role author
author
author
author
dc.subject.none.fl_str_mv B Vitamins
Co-Factor Starvation
Drug Discovery
Mrsa
Multi Drug Resistance
Pro-Drug
Suicide Drug
topic B Vitamins
Co-Factor Starvation
Drug Discovery
Mrsa
Multi Drug Resistance
Pro-Drug
Suicide Drug
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.
Fil: Drebes, Julia. Universitat Hamburg; Alemania
Fil: Künz, Madeleine. Universitat Hamburg; Alemania
Fil: Pereira, Claudio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Betzel, Christian. Universitat Hamburg; Alemania
Fil: Wrenger, Carsten. Universidade de Sao Paulo; Brasil
description Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.
publishDate 2014
dc.date.none.fl_str_mv 2014-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/20403
Drebes, Julia; Künz, Madeleine; Pereira, Claudio Alejandro; Betzel, Christian; Wrenger, Carsten; MRSA infections: from classical treatment to suicide drugs; Bentham Science Publishers; Current Medicinal Chemistry; 21; 15; 2-2014; 1809-1819
0929-8673
1875-533X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/20403
identifier_str_mv Drebes, Julia; Künz, Madeleine; Pereira, Claudio Alejandro; Betzel, Christian; Wrenger, Carsten; MRSA infections: from classical treatment to suicide drugs; Bentham Science Publishers; Current Medicinal Chemistry; 21; 15; 2-2014; 1809-1819
0929-8673
1875-533X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/118131/article
info:eu-repo/semantics/altIdentifier/doi/10.2174/0929867320666131119122520
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083222720479232
score 13.22299

Publicaciones similares